Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry

Journal of Chromatography A

Volumn 1381, Issue , 2015, Pages 132-139

  Byeon, Seul Kee ^a   Lee, Ju Yong ^a   Lee, Jin Sung ^b   Moon, Myeong Hee ^a  

^a Yonsei University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Enzyme replacement therapy; Gaucher disease; Lipid profiling; Monohexosylceramide (MHC); NLC ESI MS MS

Indexed keywords

DISEASE CONTROL; ENZYMES; LIPIDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

AVERAGE CONCENTRATION; ENZYME REPLACEMENT THERAPY; ESI-MS/MS; GAUCHER DISEASE; GLUCOCEREBROSIDASE; LIPID ACCUMULATIONS; MONOHEXOSYLCERAMIDE (MHC); NANOFLOW LIQUID CHROMATOGRAPHIES;

PATIENT TREATMENT;

LIPID; CERAMIDE MONOHEXOSIDE; CEREBROSIDE; DIHEXOSYLCERAMIDE; GLYCOSPHINGOLIPID; SPHINGOMYELIN;

ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID; CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; LIPID ANALYSIS; LIPID STORAGE; LIPIDOMICS; NANOFLUID LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; THERAPY EFFECT; URINALYSIS; BLOOD; CASE CONTROL STUDY; ECHOGRAPHY; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; PROCEDURES; TANDEM MASS SPECTROMETRY; URINE;

CASE-CONTROL STUDIES; CEREBROSIDES; CHROMATOGRAPHY, LIQUID; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLYCOSPHINGOLIPIDS; HUMANS; LIPIDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOMYELINS; TANDEM MASS SPECTROMETRY;

EID: 84922802242     PISSN: 00219673     EISSN: 18733778     Source Type: Journal    
DOI: 10.1016/j.chroma.2015.01.004     Document Type: Article

References (35)

1. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., Grewal R.P., Yu K.-T. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 1991, 324:1464-1470.
2. Wong K., Sidransky E., Verma A., Mixon T., Sandberg G.D., Wakefield L.K., Morrison A., Lwin A., Colegial C., Allman J.M., Schiffmann R. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Met. 2004, 82:192-207.
3. Meikle P.J., Whitfield P.D., Rozaklis T., Blacklock D., Duplock S., Elstein D., Zimran A., Mengel E., Cannell P., Hopwood J.J., Fuller M. Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cell Mol. Dis. 2008, 40:420-427.
4. Burrow T.A., Barnes S., Grabowski G.A. Prevalence and management of Gaucher disease. Pediatr. Health Med. Therapeut. 2011, 2:59-73.
5. Aerts J.M., Kallemeijn W.W., Wegdam W., Joao Ferraz M., van Breemen M.J., Dekker N., Kramer G., Poorthuis B.J., Groener J.E., Cox-Brinkman J., Rombach S.M., Hollak C.E., Linthorst G.E., Witte M.D., Gold H., van der Marel G.A., Overkleeft H.S., Boot R.G. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibitors. J. Inherit. Metab. Dis. 2011, 34:605-619.
6. Bodennec J., Pelled D., Riebeling C., Trajkovic S., Futerman A.H. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. FASEB J. 2002, 16:1814-1816.
7. Brouwers J.F., Vernooij E.A., Tielens A.G., van Golde L.M. Rapid separation and identification of phosphatidylethanolamine molecular species. J. Lipid Res. 1999, 40:164-169.
8. Wright M.M., Howe A.G., Zaremberg V. Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem. Cell Biol. 2004, 82:18-26.
9. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 2009, 42:1331-1346.
10. Slama L., Le Camus C., Serfaty L., Pialoux G., Capeau J., Gharakhanian S. Metabolic disorders and chronic viral disease: the case of HIV and HCV. Diabetes Metab. 2009, 35:1-11.
11. Min H.K., Lim S., Chung B.C., Moon M.H. Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Anal. Bioanal. Chem. 2011, 399:823-830.
12. Lim S., Bang D.Y., Rha K.H., Moon M.H. Rapid screening of phospholipid biomarker candidates from prostate cancer urine samples by multiple reaction monitoring of UPLC-ESI-MS/MS and statistical approaches. Bull. Kor. Chem. Soc. 2014, 35:1133-1138.
13. Kim H., Min H.K., Kong G., Moon M.H. Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry. Anal. Bioanal. Chem. 2009, 393:1649-1656.
14. Min H.K., Kong G., Moon M.H. Quantitative analysis of urinary phospholipids with breast cancer by nanoflow liquid chromatography-tandem mass spectrometry: II. Negative ion mode analysis of four phospholipid classes. Anal. Bioanal. Chem. 2010, 396:1273-1280.
15. Sutphen R., Xu Y., Wilbanks G.D., Fiorica J., Grendys E.C., LaPolla J.P., Arango H., Hoffman M.S., Martino M., Wakeley K., Griffin D., Blanco R.W., Cantor A.B., Xiao Y.J., Krischer J.P. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2004, 13:1185-1191.
16. Zhao Z., Xiao Y., Elson P., Tan H., Plummer S.J., Berk M., Aung P.P., Lavery I.C., Achkar J.P., Li L., Casey G., Xu Y. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol. 2007, 25:2696-2701.
17. Byeon S.K., Lee J.Y., Lim S., Choi D., Moon M.H. Discovery of candidate phospholipid biomarkers in human lipoproteins with coronary artery disease by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2012, 1270:246-253.
18. Kim H.Y., Wang T.C.L., Ma Y.C. Liquid chromatography/mass spectrometry of phospholipids using electrospray ionization. Anal. Chem. 1994, 66:3977-3982.
19. Han X., Gross R.W. Structural determination of lysophospholipid regioisomers by electrospray ionization tandem mass spectroscopy. J. Am. Chem. Soc. 1996, 118:451-457.
20. Hsu F.F., Turk J. Electrospray ionization/tandem quadrupole mass spectrometric studies on phosphatidylcholines: the fragmentation processes. J. Am. Soc. Mass Spectrom. 2003, 14:352-363.
21. Isaac G., Bylund D., Månsson J.E., Markides K.E., Bergquist J. Analysis of phosphatidylcholine and sphingomyelin molecular species from brain extracts using capillary liquid chromatography electrospray ionization mass spectrometry. J. Neurosci. Methods 2003, 128:111-119.
22. Taguchi R., Hayakawa J., Takeuchi Y., Ishida M. Two-dimensional analysis of phospholipids by capillary liquid chromatography/electrospray ionization mass spectrometry. J. Mass Spectrom. 2000, 35:953-966.
23. Taguchi R., Houjou T., Nakanishi H., Yamazaki T., Ishida M., Imagawa M., Shimizu T. Focused lipidomics by tandem mass spectrometry. J. Chromatogr. B 2005, 823:26-36.
24. Yu S., Li Q., Badger T.M., Fang N. Quantitative analysis of polar lipids in the nanoliter level of rat serum by liquid chromatography/mass spectrometry/mass spectrometry. Exp. Biol. Med. 2009, 234:157-163.
25. Lee J.Y., Min H.K., Choi D., Moon M.H. Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2010, 1217:1660-1666.
26. Bang D.Y., Moon M.H. On-line two-dimensional capillary strong anion exchange/reversed phase liquid chromatography-tandem mass spectrometry for comprehensive lipid analysis. J. Chromatogr. A. 2013, 1310:82-90.
27. Bligh E.G., Dyer W.J. A rapid method for total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
28. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226:497-509.
29. Byeon S.K., Lee J.Y., Moon M.H. Optimized extraction of phospholipids and lysophospholipids for nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry. Analyst 2012, 137:451-458.
30. Lim S., Byeon S.K., Lee J.Y., Moon M.H. Computational approach to structural identification of phospholipids using raw mass spectra from nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry. J. Mass Spectrom. 2012, 47:1004-1014.
31. Bang D.Y., Lim S., Moon M.H. Effect of ionization modifiers on the simultaneous analysis of all classes of phospholipids by nanoflow liquid chromatography/tandem mass spectrometry in negative ion mode. J. Chromatogr. A 2012, 1240:69-76.
32. Murph M., Tanaka T., Pang J., Felix E., Liu S., Trost R., Godwin A.K., Newman R., Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007, 433:1-24.
33. Bang D.Y., Byeon S.K., Moon M.H. Rapid and simple extraction of lipids from blood plasma and urine for liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2014, 1331:19-26.
34. Hollak C.E.M., Van Weely S., Van Oers M.H.J., Aerts J.M.F.G. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
35. Boot R.G., Verhoek M., Langeveld M., Renkema G.H., Hollak C.E.M., Weening J.J., Donker-Koopman W.E., Groener J.E., Aerts J.M.F.G. CCL18. A urinary marker of Gaucher cell burden in Gaucher patients. J. Inherit. Metab. Dis 2006, 29:564-571.